Cancer Immunology Community Seeks Better End Points
November 29, 2016
Drug developers are still hunting for surrogate end points that can better capture the benefits of checkpoint inhibitors, oncolytic viruses and modified T cell therapies.
In response to cellular stress, proteins become ensnared in chemical traffic jams, creating a kind of widespread sluggishness scientists call “proteolethargy.”
USEFUL LINKS
CONTACT
elie@eliedolgin.com
Contact Us
Thank you for contacting us. We will get back to you as soon as possible.
Oops, there was an error sending your message. Please try again later.